A detailed history of Vanguard Group Inc transactions in Cara Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 2,481,258 shares of CARA stock, worth $645,127. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,481,258
Previous 2,631,067 5.69%
Holding current value
$645,127
Previous $1.95 Million 15.98%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$0.52 - $1.05 $77,900 - $157,299
-149,809 Reduced 5.69%
2,481,258 $2.26 Million
Q4 2023

Feb 14, 2024

BUY
$0.6 - $1.65 $19,570 - $53,819
32,618 Added 1.26%
2,631,067 $1.95 Million
Q3 2023

Nov 14, 2023

BUY
$1.67 - $3.33 $7,466 - $14,888
4,471 Added 0.17%
2,598,449 $4.37 Million
Q2 2023

Aug 14, 2023

SELL
$2.83 - $4.94 $1.5 Million - $2.61 Million
-528,848 Reduced 16.93%
2,593,978 $7.34 Million
Q1 2023

May 15, 2023

BUY
$4.89 - $12.27 $103,188 - $258,921
21,102 Added 0.68%
3,122,826 $15.3 Million
Q4 2022

Feb 10, 2023

SELL
$8.88 - $12.77 $1.83 Million - $2.63 Million
-206,127 Reduced 6.23%
3,101,724 $33.3 Million
Q3 2022

Nov 14, 2022

BUY
$8.24 - $12.56 $331,223 - $504,874
40,197 Added 1.23%
3,307,851 $31 Million
Q2 2022

Aug 12, 2022

BUY
$7.45 - $13.84 $173,413 - $322,153
23,277 Added 0.72%
3,267,654 $29.8 Million
Q1 2022

May 13, 2022

BUY
$9.94 - $12.65 $2.1 Million - $2.68 Million
211,615 Added 6.98%
3,244,377 $39.4 Million
Q4 2021

Feb 14, 2022

BUY
$11.99 - $18.14 $262,365 - $396,939
21,882 Added 0.73%
3,032,762 $36.9 Million
Q3 2021

Nov 12, 2021

BUY
$11.55 - $16.06 $3.07 Million - $4.27 Million
265,783 Added 9.68%
3,010,880 $46.5 Million
Q2 2021

Aug 13, 2021

BUY
$12.38 - $29.19 $34 Million - $80.1 Million
2,745,097 New
2,745,097 $39.2 Million

Others Institutions Holding CARA

About Cara Therapeutics, Inc.


  • Ticker CARA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,725,900
  • Market Cap $14M
  • Description
  • Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and...
More about CARA
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.